Kinases and glutathione transferases: selective and sensitive targeting

Abstract

Kinases, representing almost 500 proteins in the human genome, are responsible for catalyzing the phosphorylation reaction of amino acid residues at their targets. As the largest family of kinases, the protein tyrosine kinases (PTKs) have roles in controlling the essential cellular activities, and their deregulation is generally related to pathologic conditions. The recent efforts on identifying their signal transducer or mediator role in cellular signaling revealed the interaction of PTKs with numerous enzymes of different classes, such as Ser/Thr kinases (STKs), glutathione transferases (GSTs), and receptor tyrosine kinases (RTKs). In either regulation or enhancing the signaling, PTKs are determined in close interaction with these enzymes, under specific cellular conditions, such as oxidative stress and inflammation. In this concept, intensive research on thiol metabolizing enzymes recently showed their involvement in the physiologic functions in cellular signaling besides their well known traditional role in antioxidant defense. The shared signaling components between PTK and GST family enzymes will be discussed in depth in this research review to evaluate the results of recent studies important in drug targeting for therapeutic intervention, such as cell viability, migration, differentiation and proliferation.

Keywords

glutathione transferase / protein tyrosine kinase / small molecule inhibitors / c-Src / signal transduction / drug targeting

References

[1] Abe J, Takahashi M, Ishida M, Lee J D, Berk B C (1997). c-Src is required for oxidative stress-mediated activation of big mitogen-activated protein kinase 1. J Biol Chem, 272(33): 20389–20394

[2] Adler V, Pincus M R (2004). Effector peptides from glutathione-S-transferase-pi affect the activation of jun by jun-N-terminal kinase. Ann Clin Lab Sci, 34(1): 35–46

[3] Adler V, Yin Z, Fuchs S Y, Benezra M, Rosario L, Tew K D, Pincus M R, Sardana M, Henderson C J, Wolf C R, Davis R J, Ronai Z (1999a). Regulation of JNK signaling by GSTp. EMBO J, 18(5): 1321–1334

[4] Adler V, Yin Z, Tew K D, Ronai Z (1999b). Role of redox potential and reactive oxygen species in stress signaling. Oncogene, 18(45): 6104–6111

[5] Allan J M, Wild C P, Rollinson S, Willett E V, Moorman A V, Dovey G J, Roddam P L, Roman E, Cartwright R A, Morgan G J (2001). Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc Natl Acad Sci USA, 98(20): 11592–11597

[6] Alvarez R H, Kantarjian H M, Cortes J E (2006). The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors. Cancer, 107(8): 1918–1929

[7] Aydın D, Isgor B S, Isgor Y G, Olgen S, (2010). Evaluation of Novel Indole-3-Imine-2-On Derivatives As Src Kinase and Mammalian Glutathione S-Transferase Inhibitors. 3rd International Meeting on Pharmacy and Pharmaceutical Sciences. Istanbul, Turkey: 119

[8] Baez S, Segura-Aguilar J, Widersten M, Johansson A S, Mannervik B (1997). Glutathione transferases catalyse the detoxication of oxidized metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes. Biochem J, 324(Pt 1): 25–28

[9] Ben-Bassat H, Klein B Y (2000). Inhibitors of tyrosine kinases in the treatment of psoriasis. Curr Pharm Des, 6(9): 933–942

[10] Berrier A L, Yamada K M (2007). Cell-matrix adhesion. J Cell Physiol, 213(3): 565–573

[11] Bjorge J D, Jakymiw A, Fujita D J (2000). Selected glimpses into the activation and function of Src kinase. Oncogene, 19(49): 5620–5635

[12] Board P G, Coggan M, Chelvanayagam G, Easteal S, Jermiin L S, Schulte G K, Danley D E, Hoth L R, Griffor M C, Kamath A V, Rosner M H, Chrunyk B A, Perregaux D E, Gabel C A, Geoghegan K F, Pandit J (2000). Identification, characterization, and crystal structure of the Omega class glutathione transferases. J Biol Chem, 275(32): 24798–24806

[13] Bordeleau F, Galarneau L, Gilbert S, Loranger A, Marceau N (2010). Keratin 8/18 modulation of protein kinase C-mediated integrin-dependent adhesion and migration of liver epithelial cells. Mol Biol Cell, 21(10): 1698–1713

[14] Carlucci A, Gedressi C, Lignitto L, Nezi L, Villa-Moruzzi E, Avvedimento E V, Gottesman M, Garbi C, Feliciello A (2008). Protein-tyrosine phosphatase PTPD1 regulates focal adhesion kinase autophosphorylation and cell migration. J Biol Chem, 283(16): 10919–10929

[15] Chiarugi P, Pani G, Giannoni E, Taddei L, Colavitti R, Raugei G, Symons M, Borrello S, Galeotti T, Ramponi G (2003). Reactive oxygen species as essential mediators of cell adhesion: the oxidative inhibition of a FAK tyrosine phosphatase is required for cell adhesion. J Cell Biol, 161(5): 933–944

[16] Cohen P (2000). The regulation of protein function by multisite phosphorylation—a 25 year update. Trends Biochem Sci, 25(12): 596–601

[17] Cohen S, Fleischmann R (2010). Kinase inhibitors: a new approach to rheumatoid arthritis treatment. Curr Opin Rheumatol, 22(3): 330–335

[18] Cowan-Jacob S W, Fendrich G, Manley P W, Jahnke W, Fabbro D, Liebetanz J, Meyer T (2005). The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation. Structure, 13(6): 861–871

[19] Crout C A, Koh L P, Gockerman J P, Moore J O, Decastro C, Long G D, Diehl L, Gasparetto C, Niedzwiecki D, Edwards J, Prosnitz L, Horwitz M, Chute J, Morris A, Davis P, Beaven A, Chao N J, Ali-Osman F, Rizzieri D A (2010). Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy. Cancer Invest, 28(6): 654–660

[20] Desmots F, Rissel M, Gilot D, Lagadic-Gossmann D, Morel F, Guguen-Guillouzo C, Guillouzo A, Loyer P (2002). Pro-inflammatory cytokines tumor necrosis factor alpha and interleukin-6 and survival factor epidermal growth factor positively regulate the murine GSTA4 enzyme in hepatocytes. J Biol Chem, 277(20): 17892–17900

[21] Di Pietro G, Magno L A, Rios-Santos F (2010). Glutathione S-transferases: an overview in cancer research. Expert Opin Drug Metab Toxicol, 6(2): 153–170

[22] Dincer S, Isgor B S, Isgor Y G, Olgen S (2010). Evaluation of Benzimidazole Derivatives as Src Kinase and Mammalian Glutathione S-Transferase Inhibitors. Joint Meeting of 4th International Meeting on Medicinal and Pharmaceutical Chemistry (IMMPC-4) and 6th International Symposium on Pharmaceutical Chemistry (ISPC-6). Ankara, Turkey

[23] Eaton D L, Bammler T K (1999). Concise review of the glutathione S-transferases and their significance to toxicology. Toxicol Sci, 49(2): 156–164

[24] Edelman A M, Blumenthal D K, Krebs E G (1987). Protein serine/threonine kinases. Annu Rev Biochem, 56: 567–613

[25] Frame M C (2002). Src in cancer: deregulation and consequences for cell behaviour. Biochim Biophys Acta, 1602(2): 114–130

[26] Gate L, Majumdar R S, Lunk A, Tew K D (2004). Increased myeloproliferation in glutathione S-transferase pi-deficient mice is associated with a deregulation of JNK and Janus kinase/STAT pathways. J Biol Chem, 279(10): 8608–8616

[27] Giamas G, Man Y L, Hirner H, Bischof J, Kramer K, Khan K, Ahmed S S, Stebbing J, Knippschild U (2010). Kinases as targets in the treatment of solid tumors. Cell Signal, 22(7): 984–1002

[28] Giannoni E, Buricchi F, Raugei G, Ramponi G, Chiarugi P (2005). Intracellular reactive oxygen species activate Src tyrosine kinase during cell adhesion and anchorage-dependent cell growth. Mol Cell Biol, 25(15): 6391–6403

[29] Grahn E, Novotny M, Jakobsson E, Gustafsson A, Grehn L, Olin B, Madsen D, Wahlberg M, Mannervik B, Kleywegt G J (2006). New crystal structures of human glutathione transferase A1-1 shed light on glutathione binding and the conformation of the C-terminal helix. Acta Crystallogr D Biol Crystallogr, 62(Pt 2): 197–207

[30] Griffith D, Parker J P, Marmion C J (2010). Enzyme inhibition as a key target for the development of novel metal-based anti-cancer therapeutics. Anticancer Agents Med Chem, 10(5): 354–370

[31] Gulick A M, Fahl W E (1995). Forced evolution of glutathione S-transferase to create a more efficient drug detoxication enzyme. Proc Natl Acad Sci USA, 92(18): 8140–8144

[32] Ha C H, Bennett A M, Jin Z G (2008). A novel role of vascular endothelial cadherin in modulating c-Src activation and downstream signaling of vascular endothelial growth factor. J Biol Chem, 283(11): 7261–7270

[33] Hao Q, Rutherford S A, Low B, Tang H (2006). Suppression of the phosphorylation of receptor tyrosine phosphatase-alpha on the Src-independent site tyrosine 789 by reactive oxygen species. Mol Pharmacol, 69(6): 1938–1944

[34] Harir N, Pecquet C, Kerenyi M, Sonneck K, Kovacic B, Nyga R, Brevet M, Dhennin I, Gouilleux-Gruart V, Beug H, Valent P, Lassoued K, Moriggl R, Gouilleux F (2007). Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias. Blood, 109(4): 1678–1686

[35] Hayes J D, Flanagan J U, Jowsey I R (2005). Glutathione transferases. Annu Rev Pharmacol Toxicol, 45(1): 51–88

[36] Hayes J D, Pulford D J (1995). The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol, 30(6): 445–600

[37] Holm P J, Bhakat P, Jegerschöld C, Gyobu N, Mitsuoka K, Fujiyoshi Y, Morgenstern R, Hebert H (2006). Structural basis for detoxification and oxidative stress protection in membranes. J Mol Biol, 360(5): 934–945

[38] Hosono N, Kishi S, Iho S, Urasaki Y, Yoshida A, Kurooka H, Yokota Y, Ueda T (2010). Glutathione S-transferase M1 inhibits dexamethasone-induced apoptosis in association with the suppression of Bim through dual mechanisms in a lymphoblastic leukemia cell line. Cancer Sci, 101(3): 767–773

[39] Hsu C H, Chen C L, Hong R L, Chen K L, Lin J F, Cheng A L (2002). Prognostic value of multidrug resistance 1, glutathione-S-transferase-pi and p53 in advanced nasopharyngeal carcinoma treated with systemic chemotherapy. Oncology, 62(4): 305–312

[40] Hunter T, Cooper J A (1985). Protein-tyrosine kinases. Annu Rev Biochem, 54: 897–930

[41] Huveneers S, Danen E H (2009). Adhesion signaling- crosstalk between integrins, Src and Rho. J Cell Sci, 122(Pt 8): 1059–1069

[42] Igarashi T, Tomihari N, Ohmori S, Ueno K, Kitagawa H, Satoh T (1986). Comparison of glutathione S-transferases in mouse, guinea pig, rabbit and hamster liver cytosol to those in rat liver. Biochem Int, 13(4): 641–648

[43] Ingley E (2008). Src family kinases: regulation of their activities, levels and identification of new pathways. Biochim Biophys Acta, 1784(1): 56–65

[44] Isgor B S, Coruh N, Iscan M (2010a). Soluble glutathione s-transferases in bovine liver: existence of GST T2. J Biol Sci, 10: 667–675

[45] Isgor B S, Isgor Y G, Kurt-Kılıc Z, Olgen S (2010b). The Effect of Novel pp60c-src Inhibitors on Mammalian Glutathione S-Transferase Activity. 240th ACS National Meeting & Exposition on “Chemistry of Preventing and Combatting Disease”, Boston, Massachusetts, USA

[46] Jope R S, Zhang L, Song L (2000). Peroxynitrite modulates the activation of p38 and extracellular regulated kinases in PC12 cells. Arch Biochem Biophys, 376(2): 365–370

[47] Kemble D J, Sun G (2009). Direct and specific inactivation of protein tyrosine kinases in the Src and FGFR families by reversible cysteine oxidation. Proc Natl Acad Sci USA, 106(13): 5070–5075

[48] Khadaroo R G, He R, Parodo J, Powers K A, Marshall J C, Kapus A, Rotstein O D (2004). The role of the Src family of tyrosine kinases after oxidant-induced lung injury in vivo. Surgery, 136(2): 483–488

[49] Kilic Z, Sener F, Isgor Y G, Coban T, Olgen S (2009). Investigating Antioxidant and Src Kinase Inhibitory Effects of Aminomethylindole Derivatives. 1st Turkish-Russian Joint Meeting on Organic and Medicinal Chemistry. Antalya, Turkey: 51

[50] Kilic-Kurt Z, Isgor Y G, Isgor B S, Olgen S (2010). The Effect Of Novel Indole Derivatives As Inhibitors Of Src Kinase and Mammalian Glutathione S-Transferase. Joint Meeting of 4th International Meeting on Medicinal and Pharmaceutical Chemistry (IMMPC-4) and 6th International Symposium on Pharmaceutical Chemistry (ISPC-6). Ankara, Turkey

[51] Kim S G, Lee S J (2007). PI3K, RSK, and mTOR signal networks for the GST gene regulation. Toxicol Sci, 96(2): 206–213

[52] Kim S K, Abdelmegeed M A, Novak R F (2006). Identification of the insulin signaling cascade in the regulation of alpha-class glutathione S-transferase expression in primary cultured rat hepatocytes. J Pharmacol Exp Ther, 316(3): 1255–1261

[53] Kim S K, Novak R F (2007). The role of intracellular signaling in insulin-mediated regulation of drug metabolizing enzyme gene and protein expression. Pharmacol Ther, 113(1): 88–120

[54] Kim S K, Woodcroft K J, Novak R F (2003). Insulin and glucagon regulation of glutathione S-transferase expression in primary cultured rat hepatocytes. J Pharmacol Exp Ther, 305(1): 353–361

[55] Kostyuk V A, Potapovich A I (2009). Mechanisms of the suppression of free radical overproduction by antioxidants. Front Biosci (Elite Ed), 1: 179–188 (Elite Ed)

[56] Kostyuk V A, Potapovich A I, Cesareo E, Brescia S, Guerra L, Valacchi G, Pecorelli A, Deeva I B, Raskovic D, De Luca C, Pastore S, Korkina L G (2010). Dysfunction of glutathione S-transferase leads to excess 4-hydroxy-2-nonenal and H₂O₂ and impaired cytokine pattern in cultured keratinocytes and blood of vitiligo patients. Antioxid Redox Signal, 13(5): 607–620

[57] LaPensee E W, Schwemberger S J, LaPensee C R, Bahassi M, Afton S E, Ben-Jonathan N (2009). Prolactin confers resistance against cisplatin in breast cancer cells by activating glutathione-S-transferase. Carcinogenesis, 30(8): 1298–1304

[58] Li J, Xia Z, Ding J (2005). Thioredoxin-like domain of human kappa class glutathione transferase reveals sequence homology and structure similarity to the theta class enzyme. Protein Sci, 14(9): 2361–2369

[59] Lindberg R A, Quinn A M, Hunter T (1992). Dual-specificity protein kinases: will any hydroxyl do? Trends Biochem Sci, 17(3): 114–119

[60] Lo H W, Antoun G R, Ali-Osman F (2004). The human glutathione S-transferase P1 protein is phosphorylated and its metabolic function enhanced by the Ser/Thr protein kinases, cAMP-dependent protein kinase and protein kinase C, in glioblastoma cells. Cancer Res, 64(24): 9131–9138

[61] Lu Y, Yu Q, Liu J H, Zhang J, Wang H, Koul D, McMurray J S, Fang X, Yung W K, Siminovitch K A, Mills G B (2003). Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades. J Biol Chem, 278(41): 40057–40066

[62] Manal M E T, Hanachi P, Patimah I, Siddig I A, Fauziah O (2007). The effect of neem (Azadirachta indica) leaves extract on alpha-fetoprotein serum concentration, glutathione s-transferase and glutathione peroxidase activity in hepatocarcinogenesis induced rats. Int J Cancer Res, 3: 111–118

[63] Manning G, Whyte D B, Martinez R, Hunter T, Sudarsanam S (2002). The protein kinase complement of the human genome. Science, 298(5600): 1912–1934

[64] Martin G S (2004). The road to Src. Oncogene, 23(48): 7910–7917

[65] McIlwain C C, Townsend D M, Tew K D (2006). Glutathione S-transferase polymorphisms: cancer incidence and therapy. Oncogene, 25(11): 1639–1648

[66] McLachlan R W, Kraemer A, Helwani F M, Kovacs E M, Yap A S (2007). E-cadherin adhesion activates c-Src signaling at cell-cell contacts. Mol Biol Cell, 18(8): 3214–3223

[100] McLean G W, Carragher N O, Avizienyte E, Evans J, Brunton V G, Frame M C (2005). The role of focal-adhesion kinase in cancer- a new therapeutic opportunity. Nat Rev Cancer, 5(7): 505–515<DOI OutputMedium="All"/><PubMed OutputMedium="All"/>

[67] Nordberg J, Arnér E S (2001). Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic Biol Med, 31(11): 1287–1312

[68] Nyga R, Pecquet C, Harir N, Gu H, Dhennin-Duthille I, Régnier A, Gouilleux-Gruart V, Lassoued K, Gouilleux F (2005). Activated STAT5 proteins induce activation of the PI 3-kinase/Akt and Ras/MAPK pathways via the Gab2 scaffolding adapter. Biochem J, 390(Pt 1): 359–366

[69] Oakley A J, Lo Bello M, Mazzetti A P, Federici G, Parker M W (1997). The glutathione conjugate of ethacrynic acid can bind to human pi class glutathione transferase P1-1 in two different modes. FEBS Lett, 419(1): 32–36

[70] Okamura T, Singh S, Buolamwini J, Haystead T, Friedman H, Bigner D, Ali-Osman F (2009a). Tyrosine phosphorylation of the human glutathione S-transferase P1 by epidermal growth factor receptor. J Biol Chem, 284(25): 16979–16989

[71] Okamura T, Singh S, Buolamwini J K, Friedman H S, Bigner D D, Ali-Osman F (2009b). EGF receptor tyrosine kinase mediates a novel pathway of drug resistance in malignant gliomas via tyrosine phosphorylation and functional activation of GST P1. Neuro-oncol, 11(2): 218–218

[72] Okutani Y, Kitanaka A, Tanaka T, Kamano H, Ohnishi H, Kubota Y, Ishida T, Takahara J (2001). Src directly tyrosine-phosphorylates STAT5 on its activation site and is involved in erythropoietin-induced signaling pathway. Oncogene, 20(45): 6643–6650

[73] Pani G, Giannoni E, Galeotti T, Chiarugi P (2009). Redox-based escape mechanism from death: the cancer lesson. Antioxid Redox Signal, 11(11): 2791–2806

[74] Patskovsky Y V, Patskovska L N, Listowsky I, Almo S C(2009, Last Update on 24 February, 2009). Human Glutathione S-Transferase M1A–1A Catalyzes Formation of GSH-Metal Complexes. Retrieved 20 June, 2010, from http://www.pdb.org.

[75] Planchon S M, Waite K A, Eng C (2008). The nuclear affairs of PTEN. J Cell Sci, 121(Pt 3): 249–253

[76] Playford M P, Schaller M D (2004). The interplay between Src and integrins in normal and tumor biology. Oncogene, 23(48): 7928–7946

[77] Polekhina G, Board P G, Blackburn A C, Parker M W (2001). Crystal structure of maleylacetoacetate isomerase/glutathione transferase zeta reveals the molecular basis for its remarkable catalytic promiscuity. Biochemistry, 40(6): 1567–1576

[78] Ricono J M, Huang M, Barnes L A, Lau S K, Weis S M, Schlaepfer D D, Hanks S K, Cheresh D A (2009). Specific cross-talk between epidermal growth factor receptor and integrin alphavbeta5 promotes carcinoma cell invasion and metastasis. Cancer Res, 69(4): 1383–1391

[79] Rodriguez P, Mitton B, Kranias E G (2005). Phosphorylation of glutathione-S-transferase by protein kinase C-alpha implications for affinity-tag purification. Biotechnol Lett, 27(23-24): 1869–1873

[80] Rucci N, Susa M, Teti A (2008). Inhibition of protein kinase c-Src as a therapeutic approach for cancer and bone metastases. Anticancer Agents Med Chem, 8(3): 342–349

[81] Schlaepfer D D, Hanks S K, Hunter T, van der Geer P (1994). Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase. Nature, 372(6508): 786–791

[82] Scodelaro Bilbao P, Boland R, Santillán G (2010). ATP modulates transcription factors through P2Y2 and P2Y4 receptors via PKC/MAPKs and PKC/Src pathways in MCF-7 cells. Arch Biochem Biophys, 494(1): 7–14

[83] Shah O J, Kimball S R, Jefferson L S (2002). The Src-family tyrosine kinase inhibitor PP1 interferes with the activation of ribosomal protein S6 kinases. Biochem J, 366(Pt 1): 57–62

[84] Singh S, Okamura T, Ali-Osman F (2010). Serine phosphorylation of glutathione S-transferase P1 (GSTP1) by PKCα enhances GSTP1-dependent cisplatin metabolism and resistance in human glioma cells. Biochem Pharmacol, 80(9): 1343–1355

[85] Smeyne M, Boyd J, Raviie Shepherd K, Jiao Y, Pond B B, Hatler M, Wolf R, Henderson C, Smeyne R J (2007). GSTpi expression mediates dopaminergic neuron sensitivity in experimental parkinsonism. Proc Natl Acad Sci U S A, 104(6): 1977–1982

[86] Sun G, Kemble D J (2009). To C or not to C: direct and indirect redox regulation of Src protein tyrosine kinase. Cell Cycle, 8(15): 2353–2355

[87] Tars K, Larsson A K, Shokeer A, Olin B, Mannervik B, Kleywegt G J (2006). Structural basis of the suppressed catalytic activity of wild-type human glutathione transferase T1-1 compared to its W234R mutant. J Mol Biol, 355(1): 96–105

[88] Thomas S M, Brugge J S (1997). Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol, 13(1): 513–609

[89] Tice D A, Biscardi J S, Nickles A L, Parsons S J (1999). Mechanism of biological synergy between cellular Src and epidermal growth factor receptor. Proc Natl Acad Sci U S A, 96(4): 1415–1420

[90] Townsend D M, Findlay V J, Fazilev F, Ogle M, Fraser J, Saavedra J E, Ji X, Keefer L K, Tew K D (2006). A glutathione S-transferase pi-activated prodrug causes kinase activation concurrent with S-glutathionylation of proteins. Mol Pharmacol, 69(2): 501–508

[91] Townsend D M, He L, Hutchens S, Garrett T E, Pazoles C J, Tew K D (2008). NOV-002, a glutathione disulfide mimetic, as a modulator of cellular redox balance. Cancer Res, 68(8): 2870–2877

[92] Townsend D M, Shen H, Staros A L, Gaté L, Tew K D (2002). Efficacy of a glutathione S-transferase pi-activated prodrug in platinum-resistant ovarian cancer cells. Mol Cancer Ther, 1(12): 1089–1095

[93] Uys J D, Manevich Y, Devane L C, He L, Garret T E, Pazoles C J, Tew K D, Townsend D M (2010). Preclinical pharmacokinetic analysis of NOV-002, a glutathione disulfide mimetic. Biomed Pharmacother, 64(7): 493–498

[94] Villafania A, Anwar K, Amar S, Chie L, Way D, Chung D L, Adler V, Ronai Z, Brandt-Rauf P W, Yamaizumii Z, Kung H F, Pincus M R (2000). Glutathione-S-Transferase as a selective inhibitor of oncogenic ras-p21-induced mitogenic signaling through blockade of activation of jun by jun-N-terminal kinase. Ann Clin Lab Sci, 30(1): 57–64

[95] Vosler P S, Chen J (2009). Potential molecular targets for translational stroke research. Stroke, 40(3 Suppl): S119–S120

[96] Waldmann H, Levitzki A (2001). Protein tyrosine kinase inhibitors as therapeutic agents. Bioorganic Chemistry of Biological Signal Transduction, 211: 1–15

[97] Waldron R T, Rey O, Zhukova E, Rozengurt E (2004). Oxidative stress induces protein kinase C-mediated activation loop phosphorylation and nuclear redistribution of protein kinase D. J Biol Chem, 279(26): 27482–27493

[98] Wallez Y, Cand F, Cruzalegui F, Wernstedt C, Souchelnytskyi S, Vilgrain I, Huber P (2007). Src kinase phosphorylates vascular endothelial-cadherin in response to vascular endothelial growth factor: identification of tyrosine 685 as the unique target site. Oncogene, 26(7): 1067–1077

[99] Wallez Y, Vilgrain I, Huber P (2006). Angiogenesis: the VE-cadherin switch. Trends Cardiovasc Med, 16(2): 55–59

RIGHTS & PERMISSIONS

2014 Higher Education Press and Springer-Verlag Berlin Heidelberg